Business Segments

3 Months Ended

Mar. 30, 2024

Segment Reporting [Abstract]

Business Segments

12. Business Segments

The Company operates in one segment: ophthalmology. The Company develops, manufactures and markets medical devices. Our revenues arise from the sale of consoles, delivery devices, consumables, service, and support activities.

Revenue information shown by product group is as follows (in thousands):

	Three Months Ended
	March 30, 2024		April 1, 2023
Cyclo G6	$	2,953	$	3,669
Retina		6,774		7,214
Other(1)		2,034		2,823
Total revenues	$	11,761	$	13,706

(1) Includes service contract revenues of $328 thousand and $383 thousand recognized during the three months ended March 30, 2024 and April 1, 2023, respectively. Includes $364 thousand recognized revenue related to the exclusive distribution rights during both of the three months ended March 30, 2024 and April 1, 2023. Other also includes revenues from paid service, royalty, freight and legacy G probes.

Revenue information shown by geographic region, based on the sales destination, is as follows (in thousands):

	Three Months Ended
	March 30, 2024		April 1, 2023
United States	$	5,321	$	6,774
Europe, Middle East and Africa		3,698		4,177
Asia/Pacific Rim		2,444		2,143
Americas, excluding the U.S.		298		612
	$	11,761	$	13,706

Revenues are attributed to countries based on the location of end customers.

Other than the United States, the Netherlands accounted for at least 10% of the Company’s revenues during the three months ended March 30, 2024, representing 21%. Other than the United States, the Netherlands accounted for at least 10% of the Company’s revenues during the three months ended April 1, 2023, representing 16%. The United States accounted for 45.2% and 49.4% of revenues for the three months ended March 30, 2024 and April 1, 2023, respectively.